ZAI LAB LIMITED Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
ZAI LAB LIMITED (ZLAB) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $560.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2026-08-06
- ZAI LAB LIMITED revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-06-30 was $560.00K, a 37.22% decline year-over-year.
- ZAI LAB LIMITED revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-03-31 was $4.05M, a 384.47% increase year-over-year.
- ZAI LAB LIMITED revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-12-31 was $510.00K, a 8.60% decline year-over-year.
- ZAI LAB LIMITED revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-09-30 was $734.00K, a 75.60% increase year-over-year.
- ZAI LAB LIMITED revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2025 was $2.97M, a 116.45% increase from fiscal 2024.
- ZAI LAB LIMITED revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $1.37M.
- ZAI LAB LIMITED revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ZAI LAB LIMITED revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $2.37M, a 1043.96% increase from fiscal 2021.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $560.00K 10-Q · filed 2026-08-06 | $4.62M 10-Q · filed 2026-08-06 | $5.13M derived: sum of 3 quarters · filed 2026-08-06 | $5.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.05M 10-Q · filed 2026-05-07 | $4.57M derived: sum of 2 quarters · filed 2026-05-07 | $5.30M derived: sum of 3 quarters · filed 2026-05-07 | $6.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.24M derived: sum of 2 quarters · filed 2026-02-26 | $2.14M derived: sum of 3 quarters · filed 2026-08-06 | $2.97M 10-K · filed 2026-02-26 |
| 2025-09-30 | $734.00K 10-Q · filed 2025-11-06 | $1.63M derived: sum of 2 quarters · filed 2026-08-06 | $2.46M 10-Q · filed 2025-11-06 | $3.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $892.00K 10-Q · filed 2026-08-06 | $1.73M 10-Q · filed 2026-08-06 | $2.29M derived: sum of 3 quarters · filed 2026-08-06 | $2.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $837.00K 10-Q · filed 2026-05-07 | $1.40M derived: sum of 2 quarters · filed 2026-05-07 | $1.81M derived: sum of 3 quarters · filed 2026-05-07 | $2.21M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $558.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $976.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.37M derived: sum of 3 quarters · filed 2026-02-26 | $1.37M 10-K · filed 2026-02-26 |
| 2024-09-30 | $418.00K 10-Q · filed 2025-11-06 | $816.00K derived: sum of 2 quarters · filed 2025-11-06 | $816.00K 10-Q · filed 2025-11-06 | $816.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $398.00K 10-Q · filed 2025-08-07 | $398.00K 10-Q · filed 2025-08-07 | $398.00K derived: sum of 3 quarters · filed 2026-02-26 | $398.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $562.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $562.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $562.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.14M derived: sum of 3 quarters · filed 2025-02-27 | $1.74M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.14M derived: sum of 2 quarters · filed 2025-02-27 | $1.74M derived: sum of 3 quarters · filed 2025-02-27 | $2.37M 10-K · filed 2025-02-27 |
| 2022-09-30 | $577.00K 10-Q · filed 2023-11-07 | $1.18M derived: sum of 2 quarters · filed 2023-11-07 | $1.81M 10-Q · filed 2023-11-07 | $2.01M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $601.00K 10-Q · filed 2023-08-07 | $1.23M 10-Q · filed 2023-08-07 | $1.44M derived: sum of 3 quarters · filed 2023-08-07 | $1.44M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $629.00K 10-Q · filed 2023-05-09 | $836.00K derived: sum of 2 quarters · filed 2023-05-09 | $836.00K derived: sum of 3 quarters · filed 2023-05-09 | $836.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $207.00K 10-K · filed 2022-03-01 | $207.00K derived: sum of 2 quarters · filed 2022-11-09 | $207.00K derived: sum of 3 quarters · filed 2022-11-09 | $207.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |